Skip to main content
. 2014 Nov 16;2014:926087. doi: 10.1155/2014/926087

Figure 1.

Figure 1

Effect of policosanol on serum levels of PCSK9. (a) In Protocol I, there was no significant difference in baseline serum levels of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) between the two treatment groups (both P > 0.05). Treatment with atorvastatin 20 mg/day for 8 weeks significantly increased serum levels of PCSK9 (P = 0.002, shown as “∗”); however, when combined with policosanol 20 mg/day, it caused a trend toward increasing PCSK9, but it was not statistically significant (P = 0.184). (b) In Protocol II, there was no significant difference in baseline serum levels of plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) between the two groups (both P > 0.05). After treatment with policosanol 20 mg/day for 12 weeks, there was a trend toward decreasing PCSK9 in the policosanol group, although it did not reach statistical significance (P = 0.069, shown as “#”).